KKR set to hit the jackpot with JB Chemicals and Pharma
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
Does a for-profit motive hurt education?
A popular argument is that we must be wary of private equity investment in education because these funds operate with a profit motive that results in high fees and poor outcomes. This is selective hypocrisy complicated by a lack of choice.
Has IndiGrid cracked the green finance code?
Blending capital from investors with varying risk appetite to fund green projects has emerged as a reliable model for the KKR-backed InvIT—its latest for India's largest battery energy storage project being an example.
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.